March 30 event in Chicago also features Esperion President and CEO Roger
Newton and Senior VP of Preclinical Research and Discovery Brian Krause for
update on small molecule drug discovery program
ANN ARBOR, Mich., March 24 /PRNewswire-FirstCall/ --
Esperion Therapeutics, Inc. (Nasdaq: ESPR), a biopharmaceutical company
focused on discovering and developing high-density lipoprotein (HDL)-targeted
therapies for the treatment of cardiovascular disease, will host a special
presentation on March 30 in Chicago. The presentation will outline recent
trends in lipid regulating therapy and advances in oral small molecule drug
discovery at Esperion for the treatment of lipid disorders. Antonio M. Gotto,
Jr., M.D., D.Phil., Professor of Medicine and the Stephen and Suzanne Weiss
Dean of the Joan and Sanford I. Weill Medical College of Cornell University,
will present an update on recent trends in lipid regulating therapy. Dr.
Gotto is a member of the Board of Directors of Esperion. Roger S. Newton,
Ph.D., President and CEO of Esperion Therapeutics, and Brian R. Krause, Ph.D.,
Senior Vice President of Preclinical Research and Discovery of Esperion, will
focus on Esperion's effort to discover novel lipid regulators.
Webcast Details:
What: Special presentation on lipid regulating therapy and Esperion's
small molecule drug discovery program
Who: Antonio M. Gotto, Jr., M.D., D.Phil., Professor of Medicine and the
Stephen and Suzanne Weiss Dean of the Joan and Sanford I. Weill Medical
College of Cornell University.
Roger S. Newton, Ph.D., President and CEO, Esperion Therapeutics, Inc.
Brian R. Krause, Ph.D., Senior VP of Preclinical Research and Discovery,
Esperion Therapeutics, Inc.
When: Sunday, March 30, 5:30 p.m. Central Time, 6:30 p.m. Eastern Time
Where: Live webcast available at http://www.esperion.com . Go to Investor
Relations, click on Calendar. Replay available until April 30, 2003.
"Dr. Gotto is internationally recognized and esteemed for his work related
to lipids. This event represents a rare opportunity to learn about many of
the recent advances in the treatment of lipid disorders as well as Esperion's
own progress in the discovery and preclinical development of novel lipid
regulating agents," said Roger Newton, Ph.D., President and CEO of Esperion.
Esperion Therapeutics
Esperion Therapeutics, Inc. discovers and develops pharmaceutical products
for the treatment of cardiovascular disease. Esperion intends to
commercialize a novel class of drugs that focuses on a new treatment approach
called "HDL Therapy," which is based on the Company's understanding of high-
density lipoprotein, or HDL, function. HDL is the primary facilitator of the
reverse lipid transport, or RLT, pathway by which excess cholesterol and other
lipids are removed from arteries and other tissues and are transported to the
liver for elimination from the body. Esperion's goal is to develop drugs that
exploit the beneficial functions of HDL within the RLT pathway. Esperion
currently has several product candidates under development for the treatment
of cardiovascular disease. Esperion is listed on the Nasdaq National Market
under the symbol "ESPR." For more information, visit http://www.esperion.com .
Safe Harbor Statement
The information contained in this press release includes "forward-looking
statements" within the meaning of the Private Securities Litigation Reform Act
of 1995. These forward-looking statements are often identified by words such
as "hope," "may," "believe," "anticipate," "plan," "expect," "intend,"
"assume," and similar expressions. Forward-looking statements speak only as
of the date of this press release, reflect management's current expectations
and involve certain factors, such as risks and uncertainties, which may cause
actual results to be far different from those suggested by the Company's
forward-looking statements. These factors include, but are not limited to,
risks associated with: management's ability to successfully execute its
business strategies, including entering into any strategic partnerships or
other transactions; the progress and cost of development of the Company's
product candidates; the extent and timing of market acceptance of new products
developed by the Company or its competitors; dependence on third parties to
conduct clinical trials for these product candidates; the extent and timing of
regulatory approval, as desired or required, for the Company's product
candidates; the Company's dependence on licensing arrangements and strategic
relationships with third parties; clinical trials; manufacturing; the
Company's dependence on patents and proprietary rights; the procurement,
maintenance, enforcement and defense of the Company's patents and proprietary
rights; competitive conditions in the industry; business cycles affecting the
markets in which any of the Company's products may be sold; extraordinary
events and transactions; the timing and extent of the Company's financing
needs and the Company's access to funding, including through the equity
market; economic conditions generally or in various geographic areas; and
other factors. These factors are discussed in more detail in the Company's
filings with the Securities and Exchange Commission. The Company does not
intend to update any of these factors or to publicly announce the results of
any revisions to any of these forward-looking statements other than as
required under the federal securities laws.
Company Contact: Frank Thomas
VP, Finance and Investor Relations
Esperion Therapeutics, Inc.
(734) 222-1831
fthomas@esperion.com
Media Contact: Jim Wetmore
Berry & Company Public Relations
(212) 253-8881
jwetmore@berrypr.com
SOURCE Esperion Therapeutics, Inc.
 back to top
Related links:
http://www.esperion.com
CONTACT:
Company Contact: Frank Thomas, VP, Finance
and Investor Relations of Esperion Therapeutics, Inc.,
+1-734-222-1831, fthomas@esperion.com ; Media Contact: Jim
Wetmore of Berry & Company Public Relations, +1-212-253-8881,
jwetmore@berrypr.com , for Esperion Therapeutics, Inc.
|
